India · Delayed Price · Currency is INR NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 147.56 billion. The enterprise value is 118.17 billion.
| Market Cap | 147.56B |
| Enterprise Value | 118.17B |
Important Dates
The last earnings date was Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | Nov 20, 2025 |
Share Statistics
| Current Share Class | 179.11M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 29.59% |
| Owned by Institutions (%) | 10.47% |
| Float | 83.32M |
Valuation Ratios
The trailing PE ratio is 9.48 and the forward PE ratio is 17.42.
| PE Ratio | 9.48 |
| Forward PE | 17.42 |
| PS Ratio | 3.23 |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 7.59 |
| EV / Sales | 2.59 |
| EV / EBITDA | 6.57 |
| EV / EBIT | 7.30 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | n/a |
| Interest Coverage | 55.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 23.50% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 10.87M |
| Profits Per Employee | 3.71M |
| Employee Count | 4,199 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NATCO Pharma has paid 3.08 billion in taxes.
| Income Tax | 3.08B |
| Effective Tax Rate | 16.53% |
Stock Price Statistics
The stock price has decreased by -32.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -32.43% |
| 50-Day Moving Average | 876.28 |
| 200-Day Moving Average | 877.20 |
| Relative Strength Index (RSI) | 42.68 |
| Average Volume (20 Days) | 40,889 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 45.63 billion and earned 15.57 billion in profits. Earnings per share was 86.94.
| Revenue | 45.63B |
| Gross Profit | 37.40B |
| Operating Income | 16.08B |
| Pretax Income | 18.64B |
| Net Income | 15.57B |
| EBITDA | 17.84B |
| EBIT | 16.08B |
| Earnings Per Share (EPS) | 86.94 |
Balance Sheet
The company has 32.04 billion in cash and 2.61 billion in debt, with a net cash position of 29.44 billion.
| Cash & Cash Equivalents | 32.04B |
| Total Debt | 2.61B |
| Net Cash | 29.44B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 86.54B |
| Book Value Per Share | 482.88 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 81.97%, with operating and profit margins of 35.24% and 34.13%.
| Gross Margin | 81.97% |
| Operating Margin | 35.24% |
| Pretax Margin | 40.84% |
| Profit Margin | 34.13% |
| EBITDA Margin | 39.11% |
| EBIT Margin | 35.24% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 0.41%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 0.41% |
| Dividend Growth (YoY) | -22.22% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.41% |
| Earnings Yield | 10.55% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |